^
Association details:
| Biomarker: | BAP1 mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zolinza (vorinostat) (HDAC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
Excerpt:
Tumor GANQ, GNA11, and BAP1 mutational status must be determined on all patients; if initial testing is performed locally or not available, MSKCC or Columbia University Medical Center (CUMC) patients must consent to provide a tumor block or unstained slides to MSKCC or CUMC for central review of mutational status; if tissue is not available, a pre-treatment biopsy will be necessary for eligibility.
Trial ID:
